To prevent secondary invasive meningococcal disease (IMD) cases and outbreaks, antimicrobial prophylaxis of high-risk contacts is indicated. This study reports two ciprofloxacin-resistant Neisseria meningitidis strains in Brazil. The 3544 N. meningitidis isolates collected throughout Brazil from 2009 to 2016 were evaluated for antimicrobial resistance. Meningococcal isolates showing minimal inhibitory concentrations, MICs!0.125µg ml À1 to ciprofloxacin, were analysed to determine the presence of mutations in the quinolone resistance-determining regions (QRDRs) of gyrA and parC genes. Two ciprofloxacin-resistant N. meningitidis isolates were found, both presenting a single mutation in the quinolone resistancedetermining region of the gyrA gene. These results confirmed that ciprofloxacin is still a first-line drug for chemoprophylaxis. However, we highlight the importance of continued surveillance to monitor the trends of N. meningitidis susceptibility profiles to the antimicrobials recommended for chemoprophylaxis and IMD treatment.
Meningococcus is the leading cause of bacterial meningitis in Brazil, although the incidence rates have slightly decreased in recent years from 1.57 cases per 100 000 inhabitants in 2010 to 0.67 cases in 2015 [1] . In Brazil the fatality rates for invasive meningococcal disease (IMD) have been about 20 % in cases of meningitis and about 50 % in cases of septicaemia [2] , which are much higher than those described in the literature [3] . The timing of treatment and diagnosis is an important factor insatisfactory IMD prognosis. Close contacts of persons with IMD are at increased risk of contracting the disease. To prevent secondary cases and outbreaks, antimicrobial prophylaxis of high-risk contacts is indicated. The goal of chemoprophylaxis is the eradication of nasopharyngeal carriage of Neisseria meningitidis in contacts of the index case in order to interrupt the spread of the disease. The drugs of choice currently recommended by the Brazilian Ministry of Health for chemoprophylaxis are rifampin, ciprofloxacin and ceftriaxone [2] . The emergence of bacterial isolates with varying degrees of antimicrobial resistance is the most alarming aspect concerning the therapy of infectious diseases. The aim of the present study was to report two ciprofloxacin-resistant N. meningitidis strains in Brazil in the period 2009-2016.
During this period, the Adolfo Lutz Institute in São Paulo, which is the Brazilian National Reference Laboratory for Meningitis, received 3544 N. meningitidis isolates from all Brazilian regions, comprising 27 states. These isolates represent about 78 % of the IMD cases confirmed by culture in the country. A total of 3523 (99.4 %) out of the 3544 isolates were evaluated for antimicrobial resistance. All N. meningitidis isolates were confirmed and serogrouped using conventional methods [4] . Serotyping was performed by dot-blotting using whole cell suspensions as previously described [5] .
Multilocus sequence typing (MLST) was performed according to Maiden et al. [6] . Primers, determination of sequence alleles and designation of sequence types are described on the MLST website (http://neisseria.org/nm/typing/mlst).
Antimicrobial susceptibility testing was performed in accordance with the standards established by the Clinical and Laboratory Standards Institute (CLSI). The isolates were tested for susceptibility to ciprofloxacin, penicillin G, rifampin, chloramphenicol, ceftriaxone and minocycline by the broth microdilution method for determination of minimum inhibitory concentrations (MICs) [7] , and to azithromycin by the agar disc diffusion method [8] . The results were interpreted according to the CLSI document M100-S27 (2017) [9] .
Meningococcal isolates showing MICs!0.125 µg ml À1 to ciprofloxacin were analysed to determine the presence of mutations in the quinolone resistance-determining regions (QRDRs) of gyrA (DNA gyrase, 847 bp) and parC genes (Topoisomerase IV, 822 bp) [10] [11] [12] [13] as described by Wu et al. [14] . Nucleic acid sequencing was performed by the Sanger method, using BigDye terminators (Applied Biosystem, FSTC, CA). Analysis of nucleotide sequences was performed using the Chromas and Clustal X computer software packages, and the online Internet programs BLAST and PROSITE on the National Center for Biotechnology Information website (http://www.ncbi.nlm.nih.gov/). ). Both isolates presented a threonine (Thr) fi isoleucine (Ile) mutation at amino acid 91 located in the QRDR of the gyrA gene. No additional mutations were found in the QRDRs of gyrA or parC genes ( Table 1 ).
The isolates reported herein belong to two important and well-described hyper-virulent clones: serogroup C/ST-103 complex and W/ST-11 complex. Serogroup W:2a:P1.5,2: ST11 is frequently found in several Latin American countries, circulating also in Brazil [15, 16] . Serogroup C:23: P1.14-6:ST-103 represented 75.4 % of IMD cases in 2009 in Brazil [17] . Since these clones are well established in our region and are responsible for most IMD cases by serogroups C and W, we therefore discarded a potential foreign source of such isolates.
Mutations within the QRDR of gyrA, gyrB, parC and parE genes, and in the mtrR gene have been analysed to characterize fluoroquinolone resistance in N. meningitidis isolates [12, 13] . However, the main mechanism for ciprofloxacin resistance in these organisms appears to involve single mutations in the gyrA gene [13] , resulting in amino acid substitutions Asp95Gly, Asp95Asn, Asn103 Asp, Ile111Val, Table 1 .
Characterization of ciprofloxacin-resistant Neisseria meningitidis isolates in Brazil
Strain number , have been reported occasionally by Argentina, Australia, Canada, France, North Americaand Spain [11-14, 16, 18-20] . In our study, both isolates presented a threonine (Thr) fi isoleucine (Ile) mutation at amino acid 91 located in the QRDR of the gyrA gene, resulting in increased MICs (0.125 and 0.250 µg ml À1 ). Additionally, Hong et al. [21] showed in animal tests that the Thr91Ile mutation in gyrA was associated with the persistence of bacteria in infected mice despite ciprofloxacin treatment.
According to data from the SIREVA II network, a laboratory-based regional surveillance system and to the authors' knowledge, there is no report on the circulation of ciprofloxacin-non- [12] . Sorhouet-Pereira et al. [16] , also in Argentina, reported two isolates resistant to ciprofloxacin (MIC=0.125 µg ml À1 ) belonging to the same W:2a:P1.5.2: ST-11 complex, and with the same mechanism of resistance as that described herein (gyrA Thr91Ile mutation)
The results clearly confirm that ciprofloxacin is still a firstline drug for chemoprophylaxis given the very small number of resistant isolates. However, we highlight the importance of continued surveillance to monitor the trends of N. meningitidis susceptibility profiles to the antimicrobials recommended for chemoprophylaxis and IMD treatment.
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